WELL Health Technologies' WELLTRUST™ platform has reached over 100,000 patient consents since its launch in February 2026, enabling patients to be contacted for clinical trials matching their health profiles. This milestone was achieved organically through in-clinic enrollment using WELLSTAR's OceanMD platform, which integrates consent capture into patient check-ins and EMRs. WELL and HEALWELL AI plan to expand WELLTRUST™ by increasing EMR connectivity and digital consent channels, aiming to build one of North America's largest consented patient networks for clinical trials. The platform uses HEALWELL's DARWEN™ AI to match patients with trial protocols, improving recruitment speed and precision, potentially reducing delays in clinical research.
Sempra celebrated its growth by ringing the opening bell at the NYSE, highlighting its $65 billion capital plan focused on expanding and modernizing energy infrastructure in major U.S. markets, especially California and Texas. The company aims to gen...
Filament Health has shipped its patented psilocybin drug candidate PEX010 to Austin Health in Melbourne for the PSI-PHY trial, the first study to combine psilocybin-assisted physiotherapy for refractory motor functional neurological disorder (FND). S...
Affirm reported strong double-digit growth in gross merchandise volume and active users in Q4, fueled by increased adoption of its Buy Now Pay Later (BNPL) services and rapid uptake of the Affirm Card, which now accounts for 20% of total GMV. Despite...
The JPMorgan Equity Premium Income ETF (JEPI) delivers attractive monthly income by selling call options, which caps its upside potential. In contrast, three Dividend Kings—Coca-Cola, Johnson & Johnson, and Procter & Gamble—offer lower initial yields...
Rene Haas, CEO of chip designer Arm Holdings, predicts that AI will eventually find a cure for cancer within our lifetime by solving complex DNA modeling problems. He highlighted that current AI and human capabilities are insufficient but expect adva...
